Pancreatic A- and B-cell responses to intravenous arginine in cancer of the head of the pancreas: relation to clinical features.
The endocrine pancreatic functions were evaluated in 19 patients with pancreatic head cancer by measuring plasma immunoreactive pancreatic glucagon (IRG) and insulin (IRI) responses to an intravenous dose of 30 g of arginine. The IRG responses differed by level of urinary amylase excretion, degree of glucose intolerance and degree of exocrine insufficiency. Higher IRG responses were observed in the nondiabetic subset, the hyperamylasuric subset, and the mild to moderate exocrine insufficient subset than in the corresponding opposites. Even higher responses were also found in the subset with all 3 characteristics, suggesting better preservation of the pancreatic tissue, than in that with 2 or fewer. The results obtained suggest that A-cell function increases in the earlier stages of pancreatic head cancer.
Hayakawa
T
T
Suzuki
T
T
Okumura
N
N
Noda
A
A
Kondo
T
T
D000681:Amylases / Q000652:urine; D001120:Arginine / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005934:Glucagon / Q000032:analysis; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007158:Immunologic Techniques; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood / Q000276:immunology; D007515:Islets of Langerhans / Q000503:physiopathology*; D007565:Jaundice / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000209:etiology; D010179:Pancreas / Q000032:analysis; D010190:Pancreatic Neoplasms / Q000503:physiopathology*; D013997:Time Factors
D007328:Insulin; D005934:Glucagon; D001120:Arginine; D000681:Amylases; D005947:Glucose